SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions discloses a proposed all-stock acquisition to buy EMJ Crypto Technologies, CCC Crypto Corp. and related intellectual property for an aggregate purchase price of approximately $55 million under a Share Exchange and Asset Transfer Agreement dated December 16, 2025 (amended March 11, 2026). The prospectus covers up to 550,000,000 SRXH common shares issuable as consideration, including exchangeable shares and pre-funded warrants. The Board recommended the Transaction and certain stockholders holding 14,180,156 shares (representing 51.15%) delivered written consents approving the proposals; no proxy solicitation will occur. The parties expect the closing in Q2 2026, subject to customary conditions and NYSE American and other regulatory approvals.
SRx Health Solutions, Inc. proposes an all‑stock acquisition of EMJ Crypto Technologies Inc., CCC Crypto Corp. and related IP for an aggregate purchase price of approximately $55.0 million. The transaction contemplates issuing up to 550,000,000 SRXH common shares (including exchangeable shares and pre‑funded warrants) and could increase outstanding common shares by 20% or more. The Transfer Agreement was approved by written consent representing 51.15% of outstanding voting stock and includes customary closing conditions, regulatory approvals (including NYSE American listing), a fairness opinion from Hyperion Capital Inc., and termination rights. The parties expect accounting treatment as an asset acquisition under ASC 805 and anticipate a closing in Q2 2026, subject to satisfaction or waiver of conditions.
SRx Health Solutions, Inc. announced that its wholly owned subsidiary, Halo, Purely for Pets, Inc., has invested more than 10% of the company’s aggregate treasury assets in Astro Investment XVII, an affiliate of Astro Capital structured as a special purpose vehicle.
The company and EMJ Crypto Technologies highlighted that this represents an investment of greater than 10% of their investable capital, targeting opportunities at the intersection of artificial intelligence and space-related businesses. The disclosure also notes that SRx has filed a Registration Statement on Form S-4 covering common stock to be issued in its previously announced merger with EMJX, with an information statement/prospectus to be sent to stockholders after effectiveness.
SRx Health Solutions, Inc. released a shareholder letter from EMJ Crypto Technologies founder Eric M. Jackson updating on their proposed merger and EMJX’s recent performance. EMJX deployed $18 million into its second-generation digital-asset treasury hedging strategy, earning a 5.69% return in March 2026 versus a 4.98% decline in the S&P 500, a 10.67% outperformance. Through mid-April, EMJX reports approximate gains of 3.5% in its hedging pool and 8% in long treasury holdings. The Company filed a Form S-4 registration statement for the merger, after which a regulatory review is expected before the transaction can close.
SRx Health Solutions, Inc. proposes an all-stock acquisition to buy EMJ Crypto Technologies Inc., CCC Crypto Corp. and related IP for an aggregate purchase price of approximately $55.00 million pursuant to a Share Exchange and Asset Transfer Agreement dated December 16, 2025 (amended March 11, 2026). The prospectus covers 418,250,951 shares of Common Stock that may be issued in the Transaction, based on an assumed price per share of $0.1315 (20‑Day VWAP as of April 10, 2026).
The Transferors are expected to hold approximately 46.43% of outstanding Common Stock after the Closing assuming 482,624,700 shares outstanding prior to the Closing. The Board unanimously approved the Transaction, received a fairness opinion from Hyperion Capital Inc., and stockholders holding 51.15% executed written consents approving the proposals. The Transaction is expected to close in Q2 2026, subject to customary conditions, regulatory approvals and NYSE American listing requirements.
SRx Health Solutions, Inc. Chief Executive Officer Kent Douglas Cunningham reported multiple equity awards that increase his ownership exposure, with no sales disclosed. On March 16, 2026, he received 247,522 Series B Warrants with an exercise price of $0.3182 per share, exercisable into the same number of common shares and expiring on March 16, 2029. On the same date he was also granted 63 shares of Series B Preferred Stock at $800 per share. Earlier awards include common stock grants of 231,193 shares on August 25, 2025 and 200,000 shares on December 3, 2025, both recorded as grants/awards rather than open-market purchases. One 44,464-share common stock position is held indirectly through Halo Spin-Out SPV Inc. The filing also reports a prior grant of 8,000 stock options with a $5.00 exercise price and 8,000 underlying common shares, along with several smaller common stock awards, all categorized as compensation-related acquisitions.
SRx Health Solutions, Inc. Chief Executive Officer Kent Douglas Cunningham filed an initial Form 3 reporting his ownership in the company. The filing lists 610,596 shares of common stock held directly, plus 44,464 common shares held indirectly through Halo Spin-Out SPV, Inc.
He also reports 63 shares of Series B Preferred Stock. In addition, he holds options covering 8,000 shares with a $5.0000 exercise price expiring on June 26, 2034, and Series B Warrants for 247,522 underlying shares with a $0.3182 exercise price expiring on March 16, 2029. This Form 3 records existing positions rather than new market transactions.
Conway Simon Alexander Malcolm reported acquisition or exercise transactions in this Form 4 filing.
SRx Health Solutions, Inc. director Conway Simon Alexander Malcolm reported two compensation-related stock awards of common shares. On August 25, 2025, he received 154,128 shares at a stated value of $0.40 per share, and on December 3, 2025, he received 630,000 shares at $0.39 per share. These are classified as grants or awards, not open‑market purchases. Following the most recent award, he directly holds 834,792 common shares.
SRx Health Solutions entered into a private placement Securities Purchase Agreement for up to 10,000 shares of Series B convertible preferred stock and accompanying warrants, for an aggregate purchase price of up to $8.0 million in one or more closings.
At the initial closing on March 16, 2026, investors purchased 5,660 Series B shares and 22,237,666 warrants for cash proceeds of approximately $4.528 million. Each Series B share has a stated value of $1,000, ranks senior to common stock (pari passu with Series A), and is convertible at a fixed price of $0.3182 per common share, subject to adjustments.
After stockholder approval, holders may elect alternative conversion prices tied to recent volume-weighted average prices, and the company may redeem all outstanding Series B at 125% of a defined conversion amount. The company agreed to register for resale common shares issuable upon conversion of the Series B and exercise of the warrants under a registration rights agreement.